HomeAI · summaries
Storia in 4 fonti
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks - Alnylam Pharmaceutic
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.
- ·
biopharmadive.com
Alnylam plunges as earnings deliver ‘one-two punch’
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
